Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Group A Streptococcal Vaccine
- Development stage
- Preclinical
- Lead developer
- Olymvax
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Olymvax's Group A Streptococcal Vaccine is a recombinant protein-based vaccine candidate currently in preclinical development for the prevention of infections caused by *Streptococcus pyogenes* (Group A Streptococcus). The vaccine is designed to address the significant global health burden of Group A Streptococcal (GAS) diseases, which range from common infections like pharyngitis (strep throat) and impetigo to severe invasive conditions such as necrotizing fasciitis and streptococcal toxic shock syndrome. Furthermore, the vaccine aims to prevent serious post-infectious complications, including acute rheumatic fever and rheumatic heart disease. By utilizing recombinant protein technology, Olymvax intends to produce a stable and effective immunogen that can elicit broad protection against various GAS serotypes, potentially overcoming the challenges associated with the high diversity of the bacterial M protein.
- Other names
- Recombinant Group A Streptococcal VaccineGAS vaccine
02
Targets
SpyCEP (Streptococcus pyogenes cell envelope protease)M protein (SARS-CoV-2 membrane protein)
Beyond the preview
Go deeper on Group A Streptococcal Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Group A Streptococcal Vaccine.